Product Description: Cintirorgon (LYC-55716) is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival[1][2].
Applications: Cancer-programmed cell death
Formula: C27H23F6NO6S
References: [1]Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors. Jan 04, 2017.
CAS Number: 2055536-64-4
Molecular Weight: 603.53
Compound Purity: 99.95
Research Area: Cancer
Solubility: DMSO : ≥ 113.3 mg/mL/Ethanol : 100 mg/mL (ultrasonic)
Target: ROR